The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
The multiple sclerosis community has reacted enthusiastically to mid-stage data on MediciNova Inc.'s ibudilast which suggests that the drug could be a potential new therapy for people living with progressive forms of the disease for whom there are very limited treatment options.
Full data from the SPRINT-MS Phase II study have been published in the New England Journal of Medicine, having been...
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Series B cash will be used to advance its Stargardt disease gene therapy.
